Quick Answer
GT Biopharma, Inc. reported Stockholders Equity of $5.79 million for fiscal year 2025.
GT Biopharma, Inc. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | $5.79M | +92.9% |
| 2025 | $3.00M | +111.6% |
| 2025 | -$25.88M | -1449.4% |
| 2024 | -$1.67M | -122.3% |
| 2023 | $7.48M | -36.3% |
| 2022 | $11.73M | -46.4% |
| 2021 | $21.91M | +174.4% |
| 2020 | -$29.43M | +1.2% |
| 2020 | -$29.78M | -8.3% |
| 2020 | -$27.50M | -42.4% |
| 2019 | -$19.31M | -269.8% |
| 2018 | $11.37M | -95.5% |
| 2017 | $251.69M | +1430.0% |
| 2016 | -$18.92M | +69.4% |
| 2015 | -$61.83M | -109.1% |
| 2014 | -$29.57M | -366.9% |
| 2013 | -$6.33M | +0.0% |
| 2012 | -$6.34M | -24.2% |
| 2011 | -$5.10M | +6.7% |
| 2010 | -$5.47M | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $3.00M | +43.1% | +4.9% |
| June 30, 2025 | $2.86M | -48.1% | +391.9% |
| March 31, 2025 | -$980.0K | -118.4% | +41.3% |
| December 31, 2024 | -$1.67M | -122.3% | -179.6% |
| September 30, 2024 | $2.10M | -79.0% | -61.9% |
| June 30, 2024 | $5.51M | -53.2% | +3.7% |
| March 31, 2024 | $5.31M | -59.3% | -28.9% |
| December 31, 2023 | $7.48M | -36.3% | -25.3% |
- GT Biopharma, Inc. showed an increase of +92.9% in Stockholders Equity compared to the prior fiscal year.
- Over the 2010–2025 period, GT Biopharma, Inc.’s stockholders equity has grown by 205.8% (from -$5.47 million to $5.79 million).
- The most recent figure is from GT Biopharma, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 2, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: